Impact of Anesthetics on Cardioprotection Induced by Pharmacological Preconditioning.
dexmedetomidine
levosimendan
milrinone
myocardial infarction
preconditioning
propofol
sevoflurane
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
21 Mar 2019
21 Mar 2019
Historique:
received:
19
02
2019
revised:
07
03
2019
accepted:
15
03
2019
entrez:
24
3
2019
pubmed:
25
3
2019
medline:
25
3
2019
Statut:
epublish
Résumé
Anesthetics, especially propofol, are discussed to influence ischemic preconditioning. We investigated whether cardioprotection by milrinone or levosimendan is influenced by the clinically used anesthetics propofol, sevoflurane or dexmedetomidine. Hearts of male Wistar rats were randomised, placed on a Langendorff system and perfused with Krebs⁻Henseleit buffer (KHB) at a constant pressure of 80 mmHg. All hearts underwent 33 min of global ischemia and 60 min of reperfusion. Three different anesthetic regimens were conducted throughout the experiments: propofol (11 μM), sevoflurane (2.5 Vol%) and dexmedetomidine (1.5 nM). Under each anesthetic regimen, pharmacological preconditioning was induced by administration of milrinone (1 μM) or levosimendan (0.3 μM) 10 min before ischemia. Infarct size was determined by TTC staining. Infarct sizes in control groups were comparable (KHB-Con: 53 ± 9%, Prop-Con: 56 ± 9%, Sevo-Con: 56 ± 8%, Dex-Con: 53 ± 9%; ns). Propofol completely abolished preconditioning by milrinone and levosimendan (Prop-Mil: 52 ± 8%, Prop-Lev: 52 ± 8%; ns versus Prop-Con), while sevoflurane did not (Sevo-Mil: 31 ± 9%, Sevo-Lev: 33 ± 7%;
Identifiants
pubmed: 30901956
pii: jcm8030396
doi: 10.3390/jcm8030396
pmc: PMC6462902
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Circulation. 2001 Aug 7;104(6):705-10
pubmed: 11489779
J Cardiovasc Pharmacol. 2004 Apr;43(4):555-61
pubmed: 15085067
Anesthesiology. 2004 Mar;100(3):569-74
pubmed: 15108970
J Cardiovasc Pharmacol. 2006 Oct;48(4):148-52
pubmed: 17086092
Eur J Pharmacol. 2008 Jan 14;578(2-3):108-13
pubmed: 17936270
Anaesthesia. 2008 Oct;63(10):1046-55
pubmed: 18627368
Clin Sci (Lond). 2009 Aug 03;117(5):191-200
pubmed: 19175358
Lancet. 2010 Feb 27;375(9716):727-34
pubmed: 20189026
Can J Anaesth. 2010 Aug;57(8):767-73
pubmed: 20461490
Br J Anaesth. 2010 Nov;105(5):589-95
pubmed: 20693178
Anesthesiology. 2010 Dec;113(6):1351-60
pubmed: 21068657
Exp Gerontol. 2012 Jan;47(1):116-21
pubmed: 22100641
Acta Anaesthesiol Scand. 2012 Jan;56(1):30-8
pubmed: 22103808
Lancet. 2013 Aug 17;382(9892):597-604
pubmed: 23953384
Pharmacol Rev. 2014 Oct;66(4):1142-74
pubmed: 25261534
N Engl J Med. 2015 Oct 8;373(15):1408-17
pubmed: 26436207
N Engl J Med. 2015 Oct 8;373(15):1397-407
pubmed: 26436208
PLoS One. 2015 Dec 15;10(12):e0144737
pubmed: 26671662
PLoS One. 2016 Mar 11;11(3):e0151025
pubmed: 26968004
J Cardiothorac Vasc Anesth. 2017 Aug;31(4):1223-1226
pubmed: 27793521
Cell Physiol Biochem. 2017;41(1):22-32
pubmed: 28135708
Acta Cir Bras. 2017 Jun;32(6):429-439
pubmed: 28700004
J Cardiovasc Pharmacol. 2017 Nov;70(5):284-289
pubmed: 28708712
Semin Thorac Cardiovasc Surg. 2018 Spring;30(1):26-33
pubmed: 29055710
Anesth Analg. 2018 Apr;126(4):1377-1380
pubmed: 29077609
J Cardiothorac Vasc Anesth. 2018 Oct;32(5):2142-2148
pubmed: 29306618
J Transl Med. 2018 Apr 27;16(1):112
pubmed: 29703217
Cardiovasc Drugs Ther. 2018 Oct;32(5):427-434
pubmed: 30120617
Eur Heart J Suppl. 2018 Dec;20(Suppl I):I2-I10
pubmed: 30555279
Crit Care Med. 2019 Mar;47(3):e250-e255
pubmed: 30608281
Circulation. 1986 Nov;74(5):1124-36
pubmed: 3769170
Circulation. 1993 Mar;87(3):893-9
pubmed: 7680290